The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis
- 16 June 2021
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 41 (10) , 2341-2357
Abstract
Background & Aims: The risk for hepatitis C virus (HCV) recurrence persists after HCV eradication with direct‐acting antivirals (DAAs), particularly in patients with ongoing high‐risk behaviours. Our aim was to assess the risk of HCV recurrence (late relapse and/or reinfection) post‐sustained virological response (SVR).Methods: We searched the literature for studies reporting HCV recurrence rates post‐SVR in PubMed, Web of Science and the Cochrane Library. Identified publications were divided into groups based on patient risk for HCV reinfection: low‐risk HCV mono‐infection, high‐risk HCV mono‐infection and a human immunodeficiency virus (HIV)/HCV coinfection. The HCV recurrence rate for each study was calculated by using events divided by the person‐years of follow‐up (PYFU). HCV recurrence was defined as confirmed, detectable HCV RNA post‐SVR.Results: In the 16 studies of low‐risk patients, the pooled recurrence rate was 0.89/1000 PYFU (95% confidence interval [CI], 0.16‐2.03). For the 19 studies of high‐risk patients, the pooled recurrence rate was 29.37/1000 PYFU (95% CI, 15.54‐46.91). For the eight studies of HIV/HCV‐coinfected patients, the pooled recurrence rate was 23.25/1000 PYFU (95% CI, 4.24‐53.39). The higher pooled estimates of recurrence in the high‐risk and HIV/HCV‐coinfected populations were predominantly driven by an increase in reinfection rather than late relapse.Conclusions: The HCV recurrence risk after achieving SVR with all‐oral DAAs therapy is low, and the risk of HCV recurrence in high‐risk and HIV/HCV‐coinfected populations was driven by an increase in reinfection rather than late relapse.Keywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20171054)
- National Natural Science Foundation of China (81703273, 81703321, 81871661)
- National Institutes of Health (1R01AI155140, AI082630, AI136715, DK108370)
- Natural Science Foundation of Yunnan Province (2019FA005)
This publication has 70 references indexed in Scilit:
- 802 FOLLOW-UP AFTER CESSATION OF THERAPY WITH DIRECT ACTING ANTIVIRALS IN CHRONIC HEPATITIS C PATIENTS – WHO IS AT RISK OF LATE RELAPSE?Journal of Hepatology, 2013
- Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infectionHepatology, 2011
- Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much MoreClinical Infectious Diseases, 2011
- A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and RibavirinGastroenterology, 2010
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003
- Natural history of chronic hepatitis CHepatology, 2002
- Introduction to therapy of hepatitis CHepatology, 2002
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- The Inverse of the Freeman-Tukey Double Arcsine TransformationThe American Statistician, 1978